Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, cap...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2019
|